The safety of rofecoxib

Bibliography

• FITZGERALD GA, PATRONO C: The coxibs, selective inhibitors of cyclooxygenase-2. N Engl. I Med. (2001) 345:433–442.
   PubMed Web of Science ®Google Scholar
• DOUGADOS M et at: Anti-inflammatory treatment effect of NSAIDs in ankylosing spondilitis (AS) patients with and without concomitant peripheral arthritis. Ann. Rheum. Dis. (2003) 62 (Suppl. 1):21.
   Google Scholar
• RUBIN BR, BURTON R, NAVARRA S et al.: Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial. Arthritis Rheum. (2004) 50(2):598–606.
   PubMed Web of Science ®Google Scholar
• MCADAM BF, CATELLA-LAWSON F, MARDINI IA, LAWSON JA, FITZGERALD GA: Systemic biosynthesis of prostacyclin by cyclooxygenase(COX)-2: The human pharmacology of a selective inhibitor of COX-2. Proc. Nati Acad. Sci. USA (1999) 96:272–277.
   PubMed Web of Science ®Google Scholar
• •First description of an imbalance in prostaglandin metabolism, promoting a prothrombotic state.
   Google Scholar
• CATELLA-LAWSON F, McADAM B, MORRISON BW et al.: Effects of specific inhibition of cyclooxygeanse-2 on sodium balance, hemodynamics and vasoactive eicosanoids. Pharmacol Exp. Ther. (1999) 289 :735–741.
   PubMed Web of Science ®Google Scholar
• CHENG HF, HARRIS RC: Cyclooxygenase, the kidney, and hypertension. Hypertension (2004) 43:525–530.
   PubMed Web of Science ®Google Scholar
• ROSSAT J, MAILLARD M, NUSSBERGER J, BRUNNER HR, BURNIER M: Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects. Clin. Pharmacol Ther. (1999) 66:76–84.
   PubMed Web of Science ®Google Scholar
• •Characterisation of the renal effects of selective COX-2 inhibition in humans.
   Google Scholar
• CHIOLERO A, MAILLARD MP, BURNIER M: Cardiovascular hazard of selective COX-2 inhibitors: myth or reality? Expert Opin. Drug Sal: (2002) 1:45–52.
   Google Scholar
• BOMBARDIER C, LAINE L, REICIN A et al.: VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N. Engl. J. Med. (2000) 343:1520–1528.
   Google Scholar
• •Large clinical trial demonstrating the beneficial GI effects of rofecoxib.
   Google Scholar
• RAY WA, STEIN CM, DAUGHERTY JR,HALL K, ARBOGAST PG, GRIFFIN MR: COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet (2002) 360:1071–1073.
   PubMed Web of Science ®Google Scholar
• JUNI P, NARTEY L, REICHENBACH S, STERCHI R, DIEPPE PA, EGGER M: Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet (2004) 364:2021–2029.
   PubMed Web of Science ®Google Scholar
• SOLOMON DH, SCHNEEWEISS S, GLYNN RJ et al: Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation (2004) 109:2068–2073.
   PubMed Web of Science ®Google Scholar
• MUKHERJEE D, NISSEN SE, TOPOL EJ: Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA (2001) 286:954–959.
   PubMed Web of Science ®Google Scholar
• KONSTAM MA, WEIR MR, REICIN A et al.: Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation (2001) 104:2280–2288.
   PubMed Web of Science ®Google Scholar
• SILVERSTEIN FE, FAICH G, GOLDSTEIN JL et al.: Gastrointestinal toxicity with celecoxib versus nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA (2000) 284:1247–1255.
   Google Scholar
• WATSON DJ, YU Q, BOLOGNESE JA, REICIN AS, SIMON TJ: The upper gastrointestinal safety of rofecoxib versus NSAIDs: an updated combined analysis. Curr. Med. Res. Opin. (2004) 20(10):1539–1548.
   PubMed Web of Science ®Google Scholar
• SCHNITZER T, BURMESTER GR, MYSLER E et al: Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet (2004) 364:665–674.
   PubMed Web of Science ®Google Scholar
• MAMDANI M, JUURLINK DN, KOPP A, NAGLIE, G, AUSTIN PC, LAUPACIS A: Gastrointestinal bleeding after the introduction of COX-2 inhibitors: ecological study. Br. Med. J. (2004) 328:1415–1416.
   PubMed Web of Science ®Google Scholar
• LUGARDON S, LAPEYRE-MESTRE M, MONTASTRUC JL: Upper gastrointestinal adverse drug reactions and cyclo-oxygenase-2 inhibitors (celecoxib and rofecoxib): a case/non-case study from the French Pharmacovigilance Database. Eur. Clin. Pharmacol (2004) 60:673–677.
   Web of Science ®Google Scholar
• QUIRALTE J, DELGADO J, SAENZ DE SAN PEDRO B et al: Safety of the new selective cyclooxygenase Type 2 inhibitors rofecoxib and celecoxib in patients with anaphylactoid reactions to nonsteroidal anti-inflammatory drugs. Ann. Allergy Asthma Immunol (2004) 93(4):360–364.
   PubMed Web of Science ®Google Scholar
• WOESSNER KM, SIMON RA, STEVENSON DD: Safety of high-dose rofecoxib in patients with aspirin-exacerbated respiratory disease. Ann. Allergy Asthma Immunol (2004) 93(4):339–344.
   PubMed Web of Science ®Google Scholar
• MARTIN-GARCIA C, HINOJOSA M, BERGES P et al.: Safety of a cyclooxygenase-2 inhibitor in patients with aspirin-sensitive asthma. Chest (2002) 121(6):1812–1817.
   PubMed Web of Science ®Google Scholar
• PHAN 0, METER P, BURNIER M: Are cyclooxygenase-2-selective inhibitors safe for the kidneys ?John- Bone Spine (2003) 70:237–241.
   Google Scholar
• BRATER DC, HARRIS C, REDFERN JS, Gertz BJ: Renal effects of COX-2-selective inhibitors. Am. J. Nephrol (2001) 21:1–15.
   PubMed Web of Science ®Google Scholar
• SCHWARTZ JI, VANDORMAEL K, MALICE MP et al: Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal salt diet. Clin. Pharmacol Ther. (2002) 72:50–61
   PubMed Web of Science ®Google Scholar
• SWAN SK, RUDY DW, LASSETER KC et al: Effect of cyclo-oxygenase-2 inhibition on renal function in elderly persons receiving a low salt diet. Ann. Intern. Med. (2000) 133:1–9.
   PubMed Web of Science ®Google Scholar
• GERTZ BJ, KRUPA D, BOLOGNESE JA, SPERLING RS, REICIN A: A comparison of adverse renovascular experiences among osteoarthritis patients treated with rofecoxib and comparator non-selective non-steroidal anti-inflammatory agents. Curr. Med. Eec. Opin. (2002) 18:82–91.
   PubMed Web of Science ®Google Scholar
• MAMDANI M, JUURLINK DN, LEE DS et al: Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet (2004) 363: 1751-1756.
   Google Scholar
• WHELTON A, MAURATH CJ, VERBURG KM, GEIS GS: Renal safety and tolerability of celecoxib, a novel cyclooxygenase-2 inhibitor. Am. J. Ther. (2000) 7:159–175.
   PubMedGoogle Scholar
• AUSTRALIAN COX-2 SPECIFIC INHIBITOR PRESCRIBING GROUP: Considerations for the safe use and prescribing of Cox-2-specific inhibitors. Med. J. Aust. (2002) 176:332–334.
   PubMed Web of Science ®Google Scholar
• WHELTON A, WHITE WB, BELLO AE, PUMA JA, FORT JG: Effects of celecoxib and rofecoxib on blood pressure and edema in patients 65 years of age with systemic hypertension and osteoarthritis. Am. I Cardiol (2002) 90:959–963.
   PubMed Web of Science ®Google Scholar
• POPE JE, ANDERSON JJ, FELSON DT: A meta-analysis of the effects of non-steroidal anti-inflammatory drugs on blood pressure. Arch. Intern. Med. (1993) 153:477–484.
   PubMed Web of Science ®Google Scholar
• HOCHERL K, ENDEMANN D, GROBECKER HF, KURTZ A: Cyclooxygenase-2 inhibition increases blood pressure in rats. BE J. Pharmacol (2002) 136:1117–1126.
   PubMed Web of Science ®Google Scholar
• QI Z, HAO CM, LANGENBACH RI et al: Opposite effects of cyclooxygenase-1 and -2 activity on the pressor response to angiotensin II. J. Clin. Invest. (2002) 110:61–69.
   PubMed Web of Science ®Google Scholar
• WHITE WB, KENT J, TAYLOR A, VERBURG KM, LEFKOWITH JB, WHELTON A: Effects of celecoxib on ambulatory blood pressure in hypertensive patients on ACE inhibitors. Hypertension (2002) 39:929–934.
   PubMed Web of Science ®Google Scholar
• SOWERS JR, WHITE WB, PITT B et al.:The Effects of Cyclooxygenase-2 Inhibitors and Nonsteroidal Anti-inflammatory Therapy on 24-Hour Blood Pressure in Patients With Hypertension, Osteoarthritis, and Type 2 Diabetes Mellitus. Arch. Int. Med. (2005) 165(2):161–168.
   PubMed Web of Science ®Google Scholar
• •Large clinical study using ambulatory blood pressure, demonstrating the effect of COX-2 inhibition on blood pressure.
   Google Scholar
• MORGAN TO, ANDERSON A, BERTRAM D: Effect of indomethacin on blood pressure in elderly people with essential hypertension well controlled on amlodipine or enalapril. Am. J. Hypertens. (2000) 13:1161–1167
   PubMed Web of Science ®Google Scholar
• SOLOMON DH, SCHNEEWEISS S, LEVIN R, AVORN J: Relationship between COX-2 specific inhibitors and hypertension. Hypertension (2004) 44:140–145.
   PubMed Web of Science ®Google Scholar
• The ALLHAT COLLABORATIVE RESEARCH GROUP: Major outcomes in high-risk hypetrensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker versus diuretic. "AMA (2002) 288:2981–2997.
   Google Scholar
• JULIUS S, KJELDSEN SE, WEBER M et al: VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet (2004) 363:2022–2031.
   Google Scholar
• FITZGERALD GA: COX-2 and beyond: approaches to prostaglandin inhibition in human disease. Nat. Rev. (2003) 2:879–890.
   Google Scholar
• ••Excellent review on COX-2 inhibition.
   Google Scholar
• SOLOMON DH, GLYNN RJ, LEVIN R, AVORN J: Nonsteroidal anti-inflammatory drug use and acute myocardial infarction. Arch. Int. Med. (2002) 162:1099–1104.
   PubMed Web of Science ®Google Scholar
• RAHME E, PILOTE L, LELORIER J: Association between naproxen use and protection against acute myocardial infarction. Arch. Int. Med. (2002) 162:1111–1115.
   PubMed Web of Science ®Google Scholar
• WATSON DJ, RHODES T, CAI B, GUESS HA: Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis. Arch. Int. Med. (2002) 162:1105–1110.
   PubMed Web of Science ®Google Scholar
• REICIN A, SHAPIRO D, SPERLING RS, BARR E, YU 0: Comparison of cardiovascular thrombotic event in patients with osteoarthritis treated with rofecoxib versus non-selective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone). Am. Cardiol (2002) 89:204–209
   PubMed Web of Science ®Google Scholar
• BRESALIER RS, SANDLER RS, QUAN H et al.: Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl. J. Med. (2005) 352: ahead of publication.
   Google Scholar
• •Clinical study demonstrating an increased incidence of cardiovascular events associated with rofecoxib.
   Google Scholar
• FARKOUH ME, KIRSHNER H, HARRINGTON RA et al: Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet (2004) 364:675–684.
   PubMed Web of Science ®Google Scholar
• OTT E, NUSSMEIER NA, DUKE PC et al: Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. J. Thorac. Cardiovasc. Surg. (2003) 125:1481–1492.
   PubMed Web of Science ®Google Scholar
• NUSSMEIER NA, WHELTON AA, BROWN MT et al: Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl. J. Med. (2005) 352: ahead of publication.
   Google Scholar
• SOLOMON SD, McMURRAY JJV, PFEFFER MA et al: Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl. J. Med. (2005) 352: ahead of publication.
   Google Scholar
• SCHONBECK U, SUKHOVA GK, GRABER P, COULTER S, LIBBY P: Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. Am. J. Pathol (1999) 155:1281–1291.
   PubMed Web of Science ®Google Scholar
• CHENEVARD R, HORLIMANN D, BECHIR M et al: Selective COX-2 inhibition improves endothelial function in coronary artery disease. Circulation (2003) 107:405–409.
   PubMed Web of Science ®Google Scholar
• BULUT D, LIAGHAT S, HANEFELD C, KOLL R, MIEBACH T, MUGGE A: Selective cyclo-oxygenase-2 inhibition with parecoxib acutely impairs endothelium-dependent vasodilatation in patients with essential hypertension. Hypertens. (2003) 21:1663–1667.
   Web of Science ®Google Scholar
• GRAHAM DJ, CAMPEN D, HUT R et al.: Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet (2005) 265:475–481.
   Google Scholar